Hydralazine and Valproic Acid Combination for Transcriptome Modification
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer treatments, including chemotherapy and radiotherapy, face challenges in achieving optimal results due to the adaptability of malignant cells and the complexity of epigenetic changes, such as DNA methylation and histone acetylation, which allow cells to develop resistance and survive harmful stimuli.
Innovation Solution
The combination of hydralazine and valproic acid or its salts, such as magnesium valproate, acts as transcriptome-modifying agents to inhibit DNA methylation and histone deacetylation, altering gene expression and making malignant cells more susceptible to chemotherapy and radiotherapy by disrupting their ability to survive and adapt.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If chemotherapy and radiotherapy are used to treat cancer, then malignant cells are killed, but malignant cells develop resistance and survive through epigenetic changes
Solution Approach 1:
The patent applies preliminary action by administering transcriptome-modifying agents (DNA methyltransferase inhibitors and histone deacetylase inhibitors) before chemotherapy or radiotherapy. This pre-treatment modifies the epigenetic state of malignant cells, preventing them from developing resistance mechanisms during subsequent chemotherapy or radiotherapy, thereby improving treatment reliability while addressing cell adaptability
Solution Approach 2:
The patent uses transcriptome-modifying agents as intermediary substances that mediate between the patient's immune system and malignant cells. These agents modify chromatin structure and gene expression patterns, creating a more favorable environment for chemotherapy and radiotherapy to work effectively while preventing cellular resistance mechanisms
2Manufacturing precision
If single gene therapy is used to block oncogenes or reactivate suppressive genes, then specific genetic alterations are targeted, but malignant cells eventually develop resistance through genome adaptability
Solution Approach 1:
The patent merges multiple therapeutic approaches by combining transcriptome-modifying agents with chemotherapy or radiotherapy in a unified treatment regimen. This combination therapy simultaneously targets multiple molecular pathways and epigenetic mechanisms, preventing malignant cells from developing resistance through single-gene adaptability while maintaining precise targeting of cancer-specific alterations
Solution Approach 2:
The patent employs a composite therapeutic strategy that integrates different classes of agents (DNA methyltransferase inhibitors, histone deacetylase inhibitors, chemotherapy agents, and/or radiotherapy) into a coordinated treatment protocol. This composite approach addresses the complexity of cancer genome adaptability by simultaneously modifying multiple epigenetic and genetic pathways
3Reliability
If epigenetic modifications are inhibited to prevent gene expression changes, then cell survival mechanisms are blocked, but treatment complexity increases
Solution Approach 1:
The patent applies universality by using transcriptome-modifying agents that simultaneously perform multiple functions: they inhibit DNA methylation, modify histone acetylation, alter gene expression patterns, and sensitize cells to chemotherapy or radiotherapy. This multi-functionality addresses treatment complexity by consolidating multiple therapeutic effects into a coordinated regimen rather than requiring separate interventions for each mechanism
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This combination enhances the cytotoxic effects of chemotherapeutic agents, induces demethylation and reactivation of suppressive genes, and inhibits histone deacetylase activity, leading to significant antitumoral effects and potential for extended or complete remissions by preventing malignant cells from surviving chemotherapy or radiotherapy-induced insults.
Implementation Method 1
hydralazine and valproic acid or any salt thereof such as magnesium valproate to assist with the treatment of the cancer jointly with chemotherapy or radiotherapy
Implementation Method 2
transcriptome-modifying agents that inhibit the machinery of DNA methylation and histone deacetylation
Data Source
AI summary
The use of transcriptome-modifying agents is disclosed in order to prevent malignant cells from undergoing the necessary genetic changes in order to combat cell insult and survive chemotherapy or radiotherapy. The combination of transcriptome-modifying agents comprises agents that inhibit the DNA methylation machinery plus a substance that inhibits histone deacetylation. A treatment kit is disclosed which includes an effective dose of hydralazine and valproic acid or a salt of same in the case of magnesium valproate, which is intended for use with radiotherapy or chemotherapy in the treatment of patients cancer.